- Conditions
- Orthostatic Hypotension, Hemodynamic Instability, Fever, Hypothermia
- Interventions
- Hydrocortisone High Dose, Hydrocortisone Low Dose
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Bunions, Postoperative Pain
- Interventions
- HTX-034 low dose, HTX-034 high dose, Luer lock applicator, Bupivacaine HCl
- Drug · Device
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Bellaire, Texas • San Antonio, Texas + 1 more
- Conditions
- Atopic Dermatitis
- Interventions
- Placebo, Upadacitinib, Topical corticosteroids (TCS)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 1,533 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
- Conditions
- ANCA-associated Vasculitis
- Interventions
- CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 39
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
- Conditions
- Adrenal Insufficiency
- Interventions
- megestrol acetate
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 65 Years to 80 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Total Knee Arthroplasty
- Interventions
- Hydrocortisone, Placebo
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- COPD
- Interventions
- Low Dose Corticosteroids, High Dose Corticosteroids
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • Plainsboro, New Jersey
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Hydrocortisone, placebo
- Drug
- Lead sponsor
- Kent State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Akron, Ohio
- Conditions
- Postoperative Pain
- Interventions
- SKY0402, Bupivacaine HCl
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 4
- States / cities
- San Clemente, California • Miami, Florida • Houston, Texas + 1 more
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)
- Drug · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more
- Conditions
- Postoperative Pain
- Interventions
- SKY0402 + bupivacaine HCl, Mid-dose SKY0402 + bupivacaine HCl
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Central Adrenal Insufficiency, Mifepristone
- Interventions
- Mifepristone
- Drug
- Lead sponsor
- Tobias Else
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Congenital Heart Disease, Disorder of Fetus or Newborn
- Interventions
- methylprednisolone (IVMP), methylprednisolone (two doses IVMP)
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- Up to 30 Days
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Covid19
- Interventions
- C144-LS and C-135-LS
- Biological
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cannabis Intoxication
- Interventions
- Cannabis, Pregnenolone 250 mg, Pregnenolone 500 mg, Placebo, Placebo brownie
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Acute Lung Injury
- Interventions
- Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis
- Drug · Other · Procedure
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- Clackamas, Oregon • Portland, Oregon
- Conditions
- Transplants and Implants
- Interventions
- Prednisone, rabbit antithymocyte globulin, Tacrolimus, Mycophenolate mofetil
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 19 Years to 74 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Total Hip Replacement
- Interventions
- Prednisone, Hydrocortisone, Placebo (for Prednisone)
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Osteoarthritis Hand, Osteoarthritis Wrist
- Interventions
- Corticosteroid injection (CSI), Low-dose radiotherapy (LDRT)
- Drug · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hantaan Virus Nephropathy, Puumala Virus Nephropathy
- Interventions
- Hantaan DNA Vaccine/Puumala DNA Vaccine
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Silver Spring, Maryland
- Conditions
- Kidney Transplantation, Graft Rejection
- Interventions
- Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA), Basiliximab, Corticosteroids
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 833 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Adrenal Insufficiency, Osteopenia, Osteoporosis, Steroid Suppression of ACTH Secretion
- Interventions
- Low Dose Cosyntropin (ACTH) stimulation test, High Dose Cosyntropin (ACTH) stimulation test
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Prader Willi Syndrome, Adrenal Insufficiency
- Interventions
- Low dose (1 mcg) ACTH stimulation test, Overnight metyrapone test
- Other
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio